BioCatalyst

Orelabrutinib (ICP-022) — catalyst calendar

1 verified catalyst event(s) referencing Orelabrutinib (ICP-022), each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-06-30
in 8d
ESTIMATED
 READOUT
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/
Phase 1/2 · Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
 Beijing InnoCare Pharma Tech Co., Orelabrutinib (ICP-022) ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.